Patents Assigned to Genentech
  • PROCESSES FOR THE PREPARATION OF PYRIMIDINYLCYCLOPENTANE COMPOUNDS
    Publication number: 20200062717
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
    Type: Application
    Filed: August 29, 2019
    Publication date: February 27, 2020
    Applicant: GENENTECH, INC.
    Inventors: Hans Iding, Reinhard Reents, Michelangelo Scalone, Francis Gosselin
  • PROCESS FOR PREPARING BTK INHIBITORS
    Publication number: 20200062762
    Abstract: Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3?-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4?]bipyridinyl-2?-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided.
    Type: Application
    Filed: July 2, 2019
    Publication date: February 27, 2020
    Applicant: Genentech, Inc.
    Inventors: Danial BEAUDRY, Theresa CRAVILLION, Francis GOSSELIN, Ngiap-Kie LIM, Sushant MALHOTRA, Qingping TIAN, Haiming ZHANG, Alexander GMEHLING, Alec FETTES, Stephan BACHMANN
  • HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS
    Publication number: 20200062769
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: October 31, 2019
    Publication date: February 27, 2020
    Applicant: Genentech, Inc.
    Inventors: James John CRAWFORD, Daniel Fred ORTWINE, BinQing WEI, Wendy B. YOUNG
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
    Publication number: 20200062779
    Abstract: Compounds and salts thereof that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 27, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark ZAK, F. Anthony ROMERO, Yun-Xing CHENG, Wei LI
  • Methods of treating cancers using PD-1 axis binding antagonists and taxanes
    Patent number: 10570213
    Abstract: The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: February 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Jeong Kim, Jeanne Cheung
  • Anti-wall teichoic antibodies and conjugates
    Patent number: 10570192
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • METHODS AND COMPOSITIONS FOR PREVENTING NORLEUCINE MISINCORPORATION INTO PROTEINS
    Publication number: 20200056218
    Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.
    Type: Application
    Filed: August 8, 2019
    Publication date: February 20, 2020
    Applicant: Genentech, Inc.
    Inventors: Michael W. LAIRD, Karthik VEERAVALLI
  • ANTI-MIC ANTIBODIES AND METHODS OF USE
    Publication number: 20200055939
    Abstract: The invention provides anti-MIC antibodies and methods of using the same.
    Type: Application
    Filed: October 27, 2017
    Publication date: February 20, 2020
    Applicant: Genentech, Inc.
    Inventors: Twyla Noelle LOMBANA, Christoph SPIESS, Jeong KIM, Evangeline TOY, Jill SCHARTNER, Zhengmao YE, Jack BEVERS, III, Ryan COOK, Marissa MATSUMOTO, Amy BERKLEY
  • HUMANIZED ANTIBODY
    Publication number: 20200055928
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: April 1, 2019
    Publication date: February 20, 2020
    Applicants: AC Immune S.A., Genentech, Inc.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information
    Patent number: 10564165
    Abstract: The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: February 18, 2020
    Assignee: GENENTECH, INC.
    Inventors: Lelia Delamarre, Patrick Lupardus, Ira Mellman, Mahesh Yadav, Suchit Jhunjhunwala, Jennie Lill
  • Bioreactors with multiple or adjustable-position agitator designs
    Patent number: 10563161
    Abstract: Described herein are bioreactor support structures configured to be used with containers having different designs, and methods for making and using such bioreactors. The support structures described herein may include two or more agitator motors and control systems or an adjustable-position agitator motor, a removable spacer and/or lid, multiple configurations for ports and probes, and multiple exhaust filter heating blankets. Also described herein are methods of manufacturing a multi-agitator motor or adjustable-position agitator motor bioreactor, as well as methods of modifying an existing support structure to be used with a container not originally designed to be used with the existing support structure, and methods for operating these bioreactors.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: February 18, 2020
    Assignee: Genentech, Inc.
    Inventors: Ekta Mahajan, Kelsey Dent, Edward Chan, Terry Hudson, Neria Daniel
  • Chagasin-based scaffold compositions, methods, and uses
    Patent number: 10562946
    Abstract: Provided are novel, non-naturally occurring chagasin scaffold proteins derived from chagasin or chagasin-like protease inhibitor proteins. Also provided are libraries of non-naturally occurring chagasin scaffold proteins and methods of using such libraries to generate non-naturally occurring chagasin scaffold proteins that specifically bind to a target ligand. The present invention further provides methods of using non-naturally occurring chagasin protein scaffold that bind to a target ligand, including diagnostic and therapeutic compositions and methods. The invention also provides novel non-naturally occurring chagasin scaffold proteins that specifically bind low density lipoprotein receptor-related protein 6 (LRP6) and novel non-naturally occurring chagasin scaffold proteins that specifically bind vascular endothelial growth factor (VEGF).
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: February 18, 2020
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Henry R. Maun
  • HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
    Publication number: 20200048354
    Abstract: The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 13, 2020
    Applicant: Genentech, Inc.
    Inventors: Sherman Fong, Mark Dennis
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20200048197
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Yanyan CHU, Steven DO, Anthony ESTRADA, Baihua HU, Aleksandr KOLESNIKOV, Xingyu LIN, Joseph P. LYSSIKATOS, Daniel SHORE, Vishal VERMA, Lan WANG, Guosheng WU, Po-wai YUEN
  • Quaternary amine compounds and antibody-drug conjugates thereof
    Patent number: 10556895
    Abstract: This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: John A. Flygare, Thomas Pillow, Leanna Staben
  • Anti-CD33 antibodies and immunoconjugates
    Patent number: 10556951
    Abstract: The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Shang-Fan Yu, Wei-Ching Liang, Yan Wu, Steven Leong, Andrew Polson
  • Anti-HER2 antibodies and immunoconjugates
    Patent number: 10556966
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • ANTI-KLK5 ANTIBODIES AND METHODS OF USE
    Publication number: 20200040103
    Abstract: The invention provides anti-KLK5 antibodies and methods of using the same.
    Type: Application
    Filed: March 13, 2019
    Publication date: February 6, 2020
    Applicant: Genentech, Inc.
    Inventors: Cecilia P. C. Chiu, Hilda Y. Hernandez-Barry, David B. Iaea, Moulay Hicham Alaoui-Ismaili, James T. Koerber, Wei Yu Lin, Kelly Loyet, Yonglian Sun, Benjamin T. Walters, Jawahar Sudhamsu
  • 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use
    Patent number: 10550117
    Abstract: The invention relates to compounds of formula (I): wherein Q, A1, A2, A3, A5, A6, A7, A8, R4a, R4b and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 4, 2020
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Aleksandr Kolesnikov, Jianwen A. Feng
  • Biheteroaryl compounds and uses thereof
    Patent number: RE47848
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Alan G. Olivero, Snahel Patel, Michael Siu, Joseph Lyssikatos, Malcolm Huestis, Terry Kellar